That study suggested metabolic syndrome and NAFLD/NASH available treatments significantly mitigated risks of COVID-19, those with home metformin glucagon-like-peptide 1 receptor agonist (GLP-1 RA) use have a non-significantly reduced odds of hospitalization [9]. The gene discussed is GLP1R; the disease is metabolic syndrome.